Skip to main content
. 2017 Aug 24;8(44):77207–77218. doi: 10.18632/oncotarget.20430

Figure 4. Effects of DUSP4 and DUSP6 silencing on cell viability after trastuzumab treatment.

Figure 4

(A) Normalized viability of SKTR and JIMT-1 cells treated with 10 μg/mL trastuzumab (T) after DUSP4 and DUSP6 silencing compared to Negative control siRNA (sc-siRNA) treated cells (mean with SEM) and (B) simplified scheme of the targets of DUSP4 and DUSP6. DUSP4 potentially promotes both survival and apoptosis by dephosphorylating ERK, JNK and p38.